Cancer stem cells (CSCs) drive tumor initiation, progression, and therapeutic resistance due
to their self-renewal and differentiation capabilities. Despite encouraging progress in cancer …

In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great
interest in both immunotherapy and non-immunogenic applications. This surge in interest …

Adipose stem cells (ASCs) have attracted considerable attention as potential therapeutic
agents due to their ability to promote tissue regeneration. However, their limited tissue repair …

Paraptosis is a non‐apoptotic and caspase‐independent programmed cell death that can
trigger immunogenic cell death (ICD) in tumor cells, representing a potent tactic to overcome …

Immunotherapy has revolutionized the cancer treatment paradigm, yet efficient
immunotherapeutic responses against immune-cold/desert cancers remain challenging …

Metabolic dysfunction-associated steatohepatitis (MASH) poses challenges for targeted
delivery and retention of therapeutic proteins due to excess extracellular matrix (ECM). Here …

Abstract mRNA therapeutics utilizing lipid nanoparticle (LNP) delivery technology represent
a medical innovation for the treatment of various diseases. Amine-derived ionizable cationic …

Realizing the immense clinical potential of mRNA-based drugs will require continued
development of methods to safely deliver the bioactive agents with high efficiency and …

Cancer immunotherapy represents a promising targeted treatment by leveraging the
patient's immune system or adoptive transfer of active immune cells to selectively eliminate …

Since the approval of the lipid nanoparticles (LNP)-mRNA vaccines against the SARS-CoV-
2 virus, there has been an increased interest in the delivery of mRNA through LNPs …